Talk:Nadolol

AdamSEOWorks (talk) 11:43, 28 October 2015 (UTC)

Beta-2 receptors in bronchiolar smooth muscle mediate BRONCHODILATION, increasing bronchiolar lumen diameter and relieving asthma symptoms; blocking these will potentiate asthma. Vascular smooth muscle contain beta-2 receptors that mediate muscle relaxation (VASODILATION); blocking these will cause vasoconstriction.

The Macula Densa cells of the Distal Convoluted Tubules (DCT) have beta-1 receptors that respond to either NaCl concentration within the tubule (also relates to flow rate) as well as SNS innervation (NE). These Macula Densa cells release prostaglandins that impact abutting JG cells of the efferent arteriole, causing renin release.

typo?
I'm not a medic/biologist but it seems to me that there's a typo in "should be avoided in asthma patients in preference of a beta-1 blocker such as propanolol", as propranolol is a nonselective blocker. Probably metoprolol or other beta-1 blocker should be mentioned. Please correct if you are sure.

typo 2?
"As nadolol, like other beta-2 blockers, inhibits the release of insulin in response to hypoglycemia,"

I'm not exactly an expert, but this sentence seems strange. Why would the body release insulin (which lowers blood sugar) in response to hypoglycemia (low blood sugar)? Is "hyperglycemia" the word that was meant? At any rate, I think this should require some sort of citation.

--Jsnow (talk) 00:04, 4 January 2009 (UTC)

Stereoisomerism
Formulae (showing indirectly two isomers) and IUPAC name (one defined stereoisomer) don't match each other. Please correct. --Jü (talk) 14:33, 12 August 2009 (UTC)
 * Still not correct stereochemistry. IUPAC name and formulae don't match each other. --Jü (talk) 15:52, 24 February 2011 (UTC)

Title for Nadolol should be in English.
The insertion of a long list of brand names for nadolol on the title line promotes confusion, adds unecessary clutter, and decreases the quality of the article. Multiple brand names are not listed on the title page for most other medications and are never listed on the title line in any publications. Furthermore, brand names often dissappear as a company ceases manufacturing of a medication. This is an English language article and the title should be in English. Furthermore the title of a medication should only list the generic name which is also the most widely accepted unique name for a medication across cultures and countries. I don't have access to the title page or I would change it myself.Leo2618 (talk) 17:58, 31 May 2011 (UTC) Additionally the use of the word chest pain as an indication for nadolol's use is invalid as there are many different types and causes for chest pain for which nadolol is not indicated. The word angina is more precise than chest pain. I'm not in favor of the uses for nadolol being part of the title line either.Leo2618 (talk) 18:03, 31 May 2011 (UTC)

Reference 3 does not show evidence of effectiveness for Nadolol.
The article claims that reference 3 provides evidence that Nadolol but in fact the reference reports "We found no new Class I or II studies published for acebutolol, atenolol, bisoprolol, carbamazepine, clonazepam, clonidine, clomipramine, fluvoxamine, guanfacine, nabumetone, nadolol, nicardipine, nifedipine, or protriptyline." The reference should be revised. Drbkimmel (talk) 17:29, 13 August 2016 (UTC)

Infantile Hemangioma
It might be interesting to add that Nadolol has been replacing Propranolol as the first line of defense in infantile hemangioma cases. I am not comfortable enough to write it myself, but someone can message me if you want some input. Rpmcruz (talk) 10:07, 20 April 2017 (UTC)